University Hospitals Seidman Cancer Center is at the forefront of cellular immunotherapy, offering advanced CAR T-cell therapy for patients with certain blood cancers. This innovative treatment involves modifying a patient's own T-cells to recognize and attack cancer cells, providing new hope for those with relapsed or treatment-resistant conditions. Discover how UH is advancing cancer treatment with CAR-T immunotherapy.
Showing of 20 results
Research Team from Wesley Center for Immunotherapy at UH Seidman Cancer Center Awarded Top Scoring Abstract Award at the 2025 International Society for Cell and Gene Therapy Annual Meeting
Dr. David Wald and his colleagues selected for their abstract "Development and Clinical Validation of a Less Than One Day CAR T-cell Therapy Manufacturing Process".
Phase 1 BAFF CAR T Clinical Trial for Patients with Relapsed and Refractory Multiple Myeloma Underway at UH Seidman Cancer Center
Study is being done through an agreement between UH and Luminary Therapeutics.
Multiple Myeloma Patients at UH Seidman Cancer Center Have New Immunotherapy Option
BAFF CAR T has important advantage for these patients - Innovations in Cancer | July 2024
Cleveland Innovation District Partners Exceeding Many Targets Set by State and JobsOhio
25 examples of progress showcase the impact of successful collaboration.
UH Seidman Researchers Slash Time Needed to Produce CAR T-Cells
Quicker process will get needed therapy to cancer patients who don’t have time to wait - Innovations in Cancer | Fall 2022
Novel Strategy to Improve CAR T-cell Efficacy in Non-Hodgkin Lymphoma Revealed in Preclinical Studies
University Hospitals Seidman Cancer Center researchers part of team finding blocking a single receptor may combat T cell dysfunction associated with poor response to therapy - Innovations in Cancer | Summer 2022